Fosamax and Osteonecrosis of the Jaw: Examining the Causal Link

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Drug Safety

General health and science communication has long served as a bridge between complex medical research and public understanding. In this tradition, audiences have been guided through evolving knowledge on topics ranging from nutrition to chronic disease prevention. The same principles of clarity and accuracy apply when examining specific pharmaceutical safety questions that have emerged in clinical practice. One such area involves the long-term use of bisphosphonate medications, which are commonly prescribed for bone density concerns. As the focus narrows from broad health education to a particular drug-safety inquiry, the transition requires careful attention to the known risk profile of these agents. The discussion now moves from general health literacy toward a more targeted examination of occupational and patient exposure contexts. Specifically, the question of whether Fosamax (alendronate) is associated with osteonecrosis of the jaw represents a shift from population-level health guidance to individual risk assessment. This pivot acknowledges that while bisphosphonates are effective for their intended use, their prolonged presence in bone tissue raises considerations for both patients and healthcare providers. The following analysis maintains the neutral, evidence-informed tone of health communication while addressing this specific exposure concern.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, which increases bone mass and reduces fracture risk. However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures. Clinical presentation and diagnosis of ONJ typically involve symptoms such as pain, swelling, infection, and delayed healing after tooth extraction or other oral surgery. The condition is generally associated with local infection and delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the jawbone showing necrotic areas that may be exposed through the oral mucosa. The multiscale characterization of jawbone provides comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. In the jaw, which has high bone remodeling rates due to daily mechanical stress and dental procedures, this suppression can lead to microdamage accumulation and impaired healing. Bisphosphonates also have anti-angiogenic properties, reducing blood supply to the jawbone, and may alter immune responses, increasing susceptibility to infection. These factors collectively contribute to the development of ONJ, particularly when combined with risk factors such as invasive dental procedures, cancer diagnosis, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Label Information

The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific section on osteonecrosis of the jaw, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also states that known risk factors for ONJ include invasive dental procedures, cancer, concomitant therapies, poor oral hygiene, and co-morbid disorders, and that the risk may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare adverse event.

Causation Considerations and Temporal Relationship

Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, as the condition improves with drug cessation and recurs with re-exposure. However, ONJ can also occur spontaneously without bisphosphonate use, and other risk factors such as dental procedures, cancer, and concomitant medications must be considered. The duration of exposure is a key factor, as the risk of ONJ may increase with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients with low fracture risk, the label recommends considering drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may reduce the risk of ONJ.

Timeline, Management, and Overall Safety Profile

The timeline between exposure and documented harm can vary widely. Symptoms may appear within days to months after starting Fosamax, but ONJ is more commonly reported after years of use, especially in patients with additional risk factors. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ, management includes stopping the bisphosphonate, addressing local infection, and avoiding invasive dental procedures. The overall safety profile of Fosamax, including adverse reactions considered possibly, probably, or definitely drug related, is similar for once-weekly and daily dosing regimens (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, Fosamax is associated with an increased risk of ONJ, particularly in patients with risk factors such as dental procedures, cancer, or prolonged use. The drug's label provides warnings about this risk and recommends preventive measures, including dental evaluation before starting therapy and consideration of drug discontinuation for invasive dental procedures. While ONJ is a rare adverse event, the evidence supports a causal relationship based on temporal association, improvement upon drug cessation, and recurrence with rechallenge.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, which increases bone mass and reduces fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does Fosamax cause osteonecrosis of the jaw?

Yes, Fosamax is associated with an increased risk of osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. The drug's label includes a specific warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk is higher in patients with additional risk factors such as invasive dental procedures, cancer, concomitant therapies, poor oral hygiene, and prolonged use.

What are the symptoms of osteonecrosis of the jaw?

Symptoms of ONJ include pain, swelling, infection, and delayed healing after tooth extraction or other oral surgery. The condition is generally associated with local infection and delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging showing necrotic areas of the jawbone.

How is the causal link between Fosamax and ONJ established?

The causal link is supported by temporal association: symptoms often improve after stopping Fosamax and may recur upon rechallenge with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ can also occur spontaneously, so other risk factors must be considered.

What should patients do if they develop ONJ while taking Fosamax?

Patients who develop ONJ should discontinue Fosamax, address local infection, and avoid invasive dental procedures. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A dental evaluation before starting therapy and consideration of drug discontinuation for invasive dental procedures are recommended preventive measures.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.